Ovarian Cancer Therapeutics - Global Strategic Business Report - Market Research Reports

Contents:

OVARIAN CANCER THERAPEUTICS
A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II.
1. Market Overview II-1
Stats to Ponder At II-1
Ovarian Cancer Therapeutics Market
Current & Future Analysis II-2
Propelled by High Relapse Rates II-1 II-2
Hopes Pinned on Emerging Immunotherapeutics II-2
MAbs to Rule the Market II-2
Next Gen Therapeutics to Watch Out For II-3
GOG Commences Phase III Trial of XYOTAX(TM) II-3
InterMune Completes Enrollment of Pivotal Phase III Trial of
Actimmune II-3
Antisoma Concludes Phase III Trials of Pemtumomab II-3
Genentech to Initiate Phase III Trials of Avastin II-4
Advaxis Seeks Partner for LOVAXIN NY Vaccine II-4
Alethia Hunts Worldwide Partner for Ovarian Cancer Therapy II-4
Other Therapeutic Drugs in the Pipeline II-4

2. Ovarian Cancer
A Synopsis II-5
Types of Ovarian Cancer II-5
Epithelial Ovarian Tumors II-5
Germ-Cell Tumors II-5
Stromal Tumors II-5
Symptoms II-6
Clinical Stages And Grades In Ovarian Cancer II-6
Stage I II-6
Stage IA II-7
Stage IB II-7
Stage IC II-7
Stage II II-7
Stage IIA II-7
Stage IIB II-7
Stage IIC II-7
Stage III II-7
Stage IIIA II-7
Stage IIIB II-7
Stage IIIC II-7
Stage IV II-7
Risk Factors II-8
Preventive Measures II-9
Inhibiting Ovulation II-9
Ligation of Fallopian Tubes II-10
Prophylactic Oophorectomy II-10
Lifestyle Factors II-10
Detection II-10
Rectal and Pelvic Examination II-11
Ultrasound Screening II-11
CA-125 Blood Test II-11
CAT/CT Scan (Computerized Axial Tomography Scan) II-11
Laparotomy II-11
Ovarian Pap Test II-12
Modes of Treatment II-12
Surgery II-12
Chemotherapy II-13
Radiation Therapy II-14
Clinical Trials (Treatment Studies) II-15

3. New Therapeutic Approaches Under Study II-16
Immunotherapy II-16
Gene Therapy II-16
Antiangiogenesis Agents II-16
Retinoids II-16
Imatinib II-17
LH-RH Agonists II-17
Epothilones II-17
Aromatase Inhibitors II-17
Matripase Inhibitors II-17
Intraperitoneal Chemotherapy II-17
High Dose Chemotherapy II-18

4. Treatment by Clinical Stages II-19
Stage IA II-19
Stage IB II-19
Stage IC II-19
Stage IIA II-19
Stages IIB, IIIA, IIIB, IIIC and IV II-20

5. Prevalent Chemotherapeutic Drugs II-21
Altretamine II-21
Capecitabine II-21
Carboplatin II-21
Cisplatin II-22
Cyclophosphamide II-22
Docetaxel II-22
Doxorubicin II-22
Etoposide II-23
Gemcitabine II-23
Ifosfamide II-23
Irinotecan II-23
Melphalan II-23
Paclitaxel II-24
Pegylated Liposomal Doxorubicin II-24
Tamoxifen II-24
Topotecan II-24
Valspodar II-24
Vinorelbine II-25

6. Analysis of Product Segments II-26
Localized Ovarian Cancer Therapeutics II-26
Metastatic Ovarian Cancer Therapeutics II-26
Relapsed/Refractory Ovarian Cancer Therapeutics II-27

7. Research And Development II-29
VEGF Fuels Tumor Angiogenesis II-29
List of Modified Taxanes is Escalating II-29
FHCRC Tries to Identify Novel Genes II-29
Combined Administration of Different Drugs is Fruitful II-29
Women are at Risk with Estrogen Therapy II-30
Tools to Visualize Disease Progress II-30
Treatment for Ovarian Cancer
The Titanium Way II-30
HSV Therapy for Advanced Ovarian Cancer II-30

8. Strategic Corporate Developments II-31
Oxford BioMedica Halts Development of Gene Therapy for
Ovarian Cancer II-31
ImmunoGen, Raven Biotechnologies Agreement Over Ovarian
Cancer Therapy Expires II-31
TopoTarget Commences PXD 101 Phase I Trials II-31
AmpliMed’s Imexon Orphan Drug Gets US FDA Grant II-31
DOXIL Obtains FDA Stamp of Approval II-31
Cell Therapeutics, Inc., Enters into an Agreement with
Gynecologic Oncology Group II-32
Raven Biotechnologies Enters into Research Collaboration with
Abbott Laboratories II-32
Ivax Gets Endorsement from European Commission for
Commercializing its Generic Form of Paclitaxel II-32
Bristol and Pierre Fabre Médicament Sign Agreement II-32
AltaRex Enters into a Licensing Agreement with United
Therapeutics II-32
Nippon Kayaku and GlaxoSmithKline Enter into an Agreement II-33
Roche to Purchase Antisoma Drugs II-33
ImmunoGen and Raven Biotechnologies Enter into Collaboration II-33
Pemtumomab Receives European Orphan Drug Status II-33
Immusol, Inc, Discovers ID4 Drug Target Gene for Breast &
Ovarian Cancer II-33
ALZAS CAELYX® Receives Endorsement from Canadian Therapeutic
Products Programme II-33
GlaxoSmithKline’s Hycamtin Receives Endorsement from UK
National Institute for Clinical Excellence II-34

9. Focus on Key Players II-35
Alza Corporation (US) II-35
Amgen Inc. (US) II-35
Bristol-Myers Squibb (US) II-35
Cell Therapeutics Inc. (US) II-36
Genentech, Inc. (US) II-36
GlaxoSmithkline Plc (UK) II-36
Immunogen Inc. (US) II-37
Ivax (US) II-37
OSI Pharmaceuticals (US) II-37
Raven Biotechnologies Inc. (US) II-37

10. Global Market Perspective II-38
Table 1: World Recent Past, Current & Future Analysis for
Ovarian Cancer Therapeutics Market by Geographic Region
US,
Canada, Japan, Europe and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graphs/Chart) II-38

Table 2: World 10-Year Perspective for Ovarian Cancer
Therapeutics Market by Geographic Region
Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe and
Rest of World Markets for Years 2000, 2005 & 2010 (includes
corresponding Graphs/Chart) II-38

III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current & Future Analysis III-1
Prevalence in the US III-1
Table 3: Estimated Cancer Cases by Site Among Women in the
US: 2004 (includes corresponding Graphs/Chart) III-1

Table 4: Estimated Cancer Deaths by Site Among Women in
the US : 2004 (includes corresponding Graphs/Chart) III-2
Associated Ovarian Cancer Therapeutics Developments III-2
Strategic Corporate Developments III-3
Focus on Key Players III-5
Alza Corporation III-5
Amgen Inc. III-5
Bristol-Myers Squibb III-5
Cell Therapeutics Inc. III-6
Genentech, Inc. III-6
Immunogen Inc III-6
Ivax III-6
OSI Pharmaceuticals III-7
Raven Biotechnologies Inc. III-7
Medarex, Inc III-7
B.Market Analytics III-8
Table 5: US Recent Past, Current & Future Analysis for
Ovarian Cancer Therapeutics Market by Product Segments -
Localized Ovarian Cancer Therapeutics, Metastatic Ovarian
Cancer Therapeutics, Refractory Ovarian Cancer Therapeutics
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2000 through 2010 (includes
corresponding Graphs/Chart) III-8

Table 6: US 10-Year Perspective for Ovarian Cancer
Therapeutics by Market Product Segments- Percentage
Breakdown of Dollar Sales for Localized Ovarian Cancer
Therapeutics, Metastatic Ovarian Cancer Therapeutics,
Refractory Ovarian Cancer Therapeutics Markets for Years
2000, 2005 & 2010 (includes corresponding Graphs/Chart) III-8

2. Canada III-9
A.Market Analysis III-9
Current and Future Analysis III-9
Ovarian Cancer Stats III-9
B.Market Analytics III-9
Table 7: Canadian Recent Past, Current & Future Analysis for
Ovarian Cancer Therapeutics Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graphs/Chart) III-9

3. Japan III-10
A.Market Analysis III-10
Current and Future Analysis III-10
B.Market Analytics III-10
Table 8: Japanese Recent Past, Current & Future Analysis for
Ovarian Cancer Therapeutics Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graphs/Chart) III-10

4. Europe III-11
A.Market Analysis III-11
Current and Future Analysis III-11
Incidence of Ovarian Cancer III-11
Table 9: Ovarian Cancer Incidence in Europe by Geographic
Region for 2002: France, Germany, Russia, UK, Italy and
Spain (includes corresponding Graphs/Chart) III-11
Strategic Corporate Developments III-11
GlaxoSmithkline Plc
A Key Player III-11
B.Market Analytics III-13
Table 10: European Recent Past, Current & Future Analysis
for Ovarian Cancer Therapeutics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2010 (includes corresponding Graphs/Chart) III-13

5. Rest of The World III-14
A.Market Analysis III-14
Current and Future Analysis III-14
Table 11: Ovarian Cancer Incidence in Major Countries in
Asia-Pacific: 2002 (includes corresponding Graphs/Chart) III-14

Table 12: Ovarian Cancer Incidence in Major Countries in
Latin America: 2002 (includes corresponding Graphs/Chart) III-14

Table 13: Ovarian Cancer Incidence in Major Countries in
Middle East: 2002 (includes corresponding Graphs/Chart) III-15

Table 14: Ovarian Cancer Incidence in Major Countries in
Africa :2002 (includes corresponding Graphs/Chart) III-15
B.Market Analytics III-15
Table 15: Rest of World Recent Past, Current & Future
Analysis for Ovarian Cancer Therapeutics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2010 (includes
corresponding Graphs/Chart) III-15

IV. COMPETITION

1. Altarex Medical Corporation (Canada) IV-1
2. Amgen, Inc. (USA) IV-2
Table 16: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-3
Table 17: Half Yearly Sales Analysis by Geographical
Region: 2004-2005 (Q1) (In US$ million) IV-3
Table 18: Annual Sales Analysis: 2003-2004 (In US$
million) IV-3

Table 19: Annual Sales Analysis by Geographical Region:
2003-2004 (In US$ million) IV-3
3. Angiotech Pharmaceuticals, Inc. (Canada) IV-6
Table 20: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-7

Table 21: Half Yearly Sales Analysis by Quarter: 2004-
2005 (H1) (In US$ million) IV-7

Table 22: Half Yearly Sales Analysis by Products: 2004
-2005 (H1) (In US$ million) IV-8
4. Antisoma PLC (UK) IV-13
5. Ariad Pharmaceuticals, Inc. (USA) IV-14
6. Balance Pharmaceuticals, Inc. (USA) IV-16
7. Bristol-Myers Squibb Company (USA) IV-17
Table 23: Annual Sales Analysis: 2003-2004 (In US$
million) IV-19

Table 24: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-19

Table 25: Annual Sales Analysis by Geographic Region:
2003-2004 (In US$ million) IV-19
8. Cell Therapeutics, Inc. (USA) IV-28
Table 26: Annual Sales Analysis: 2003-2004 (In US$
million) IV-29
9. Corixa Corporation (USA) IV-32
Table 27: Quarterly Sales Analysis: 2004-2005 (Q1) (In
US$ million) IV-32

Table 28: Annual Sales Analysis: 2003-2004 (In US$
million) IV-33
10. Dendreon Corporation (USA) IV-37
Table 29: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ Thousands) IV-38

Table 30: Annual Sales Analysis: 2003-2004 (In US$
Thousands) IV-38

Table 31: Quarterly Sales Analysis: 2003-2004 (In US$
Thousands) IV-38
11. Dr. Reddys Laboratories (India) IV-41
Table 32: Annual Sales Analysis: 2003-2005 (In INR
million) IV-42

Table 33: Annual Sales Analysis by Product Segment:
2003-2004 (In INR million) IV-43

Table 34: Annual Sales Analysis by Geographical Region:
2003-2004 (In INR million) IV-43
12. Eli Lilly and Company (USA) IV-45
Table 35: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-46

Table 36: Half Yearly Sales Analysis by Segment: 2004-
2005 (H1) (In US$ million) IV-47

Table 37: Half Yearly Sales Analysis by Product: 2004-
2005 (H1) (In US$ million) IV-47

Table 38: Annual Sales Analysis: 2003-2004 (In US$
million) IV-48

Table 39: Annual Sales Analysis by Segment: 2003-2004
(In US$ million) IV-48

Table 40: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-48

Table 41: Annual Sales Analysis by Geographical Region:
2003-2004 (In US$ million) IV-49

Table 42: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-49
13. F. Hoffmann-La Roche Ltd. (Switzerland) IV-55
Table 43: Half Yearly Sales Analysis: 2004-2005 (H1)
(In CHF millions) IV-56

Table 44: Annual Sales Analysis: 2003-2004 (In CHF
millions) IV-56

Table 45: Annual Sales Analysis by Division: 2003-2004
(In CHF millions) IV-56
Roche Diagnostics Corporation (USA) IV-61
Chugai Pharmaceutical Co., Ltd. (Japan) IV-63
Table 46: Annual Sales Analysis: 2003-2004 (In ¥
million) IV-64
14. Genaera Corporation (USA) IV-67
15. Genentech, Inc. (USA) IV-68
Table 47: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-69

Table 48: Annual Sales Analysis: 2003-2004 (In US$
million) IV-69

Table 49: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-69
16. GlaxoSmithKline PLC (UK) IV-74
Table 50: Half Yearly Sales Analysis: 2004-2005 (H1)
(In £ million) IV-75

Table 51: Half Yearly Sales Analysis by Division: 2004
-2005 (H1) (In £ million) IV-75

Table 52: Annual Sales Analysis: 2003-2004 (In £
million) IV-75

Table 53: Annual Sales Analysis by Division: 2003-2004
(In £ million) IV-75
GlaxoSmithKline PLC (UK) IV-85
17. Gynecologic Oncology Group (USA) IV-89
18. Hybridon, Inc. (USA) IV-90
19. ImmunoGen, Inc. (USA) IV-93
Table 54: Annual Sales Analysis: 2004-2005 (In US$
million) IV-94

Table 55: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-94
20. Immusol, Inc. (USA) IV-96
21. InterMune, Inc. (USA) IV-99
Table 56: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-99

Table 57: Annual Sales Analysis: 2003-2004 (In US$
million) IV-99

Table 58: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-100

Table 59: Quarterly Sales Analysis: 2003-2004 (In US$
million) IV-100
22. Introgen Therapeutics, Inc. (USA) IV-102
Table 60: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ Thousands) IV-103

Table 61: Quarterly Sales Analysis: 2004-2005 (Q1) (In
US$ Thousands) IV-103

Table 62: Annual Sales Analysis: 2003-2004 (In US$
Thousands) IV-103
23. Ivax Corporation (USA) IV-107
Table 63: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ billion) IV-108

Table 64: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-108
24. Johnson & Johnson (USA) IV-116
Table 65: Quarterly Sales Analysis: 2004-2005 (Q1) (In
US$ billion) IV-118

Table 66: Quarterly Sales Analysis By Segment: 2004-
2005 (Q1) (In US$ billion) IV-118

Table 67: Quarterly Sales Analysis By Geographical
Region: 2004-2005 (Q1) (In US$ billion) IV-118

Table 68: Annual Sales Analysis: 2003-2004 (In US$
billion) IV-118

Table 69: Annual Sales Analysis By Segment: 2003-2004
(In US$ billion) IV-119

Table 70: Annual Sales Analysis By Geographical Region:
2003-2004 (In US$ billion) IV-119

Table 71: Quarterly Sales Analysis: 2003-2004 (In US$
billion) IV-119
Alza Corporation (USA) IV-127
Janssen-Cilag International NV (Belgium) IV-129
Janssen Pharmaceutica Products, L.P. (USA) IV-130
Johnson & Johnson Pharmaceutical Research & Development
Llc (USA) IV-130
Ortho Biotech Products LP (USA) IV-131
Ortho Biotech Products
Tibotec Therapeutics (USA) IV-133
25. Marshall Edwards, Inc. (Australia) IV-134
26. MedImmune, Inc. (USA) IV-135
Table 72: Half yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-136
able 73: Half Yearly Sales Analysis by Product: 2004-
2005 (H1) (In US$ million) IV-136
Table 74: Annual Sales Analysis: 2003-2004 (In US$
million) IV-137

Table 75: Annual Sales Analysis by Product: 2003-2004
(In US$ million) IV-137
27. MGI Pharma, Inc. (USA) IV-140
28. NeoPharm, Inc. (USA) IV-142
29. OSI Pharmaceuticals, Inc. (USA) IV-145
Table 76: Half Yearly Sales Analysis: 2004-2005 (H1)
(In US$ million) IV-146

Table 77: Annual Sales Analysis: 2003-2004 (In US$
million) IV-146
30. Phytogen Life Sciences, Inc. (Canada) IV-150
31. Pierre Fabre Médicament (France) IV-151
32. Procyon Biopharma, Inc. (Canada) IV-152
33. QLT, Inc. (Canada) IV-154
Table 78: Quarterly Sales Analysis: 2004-2005 (Q1) (In
US$ million) IV-155

Table 79: Quarterly Sales Analysis by Geographical
Region: 2004-2005 (Q1) (In US$ million) IV-155

Table 80: Annual Sales Analysis: 2003-2004 (In US$
million) IV-155

Table 81: Annual Sales Analysis by Geographical Region:
2003-2004 (In US$ million) IV-155
34. Raven Biotechnologies, Inc. (USA) IV-157
35. Sanofi-Aventis (France) IV-158
Table 82: Half Yearly Sales Analysis: 2004-2005 (H1)
In € million) IV-159

Table 83: Half Yearly Sales Analysis by Segment: 2004-
2005 (H1) (In € million) IV-159

Table 84: Half Yearly Sales Analysis by Product: 2004-
2005 (H1) (In € million) IV-159
36. Schering-Plough Corporation (USA) IV-164
Table 85: Quarterly Sales Analysis by Segments: 2004-
2005 (Q1) (US$ million) IV-165

Table 86: Quarterly Sales Analysis by Regions: 2004-
2005 (Q1) (US$ million) IV-165

Table 87: Annual Sales Analysis by Segments: 2003-2004
(US$ million) IV-165

Table 88: Annual Sales Analysis by Regions: 2003-2004
(US$ million) IV-165
37. Sirna Therapeutics, Inc. (USA) IV-169
Table 89: Half Yearly Sales Analysis: 2004-2005 (In US$
million) IV-170

Table 90: Half Yearly Sales Analysis by Business
Segment: 2004-2005 (In US$ million) IV-170

Table 91: Annual Sales Analysis: 2003-2004 (In US$
million) IV-170
38. Sonus Pharmaceuticals, Inc. (USA) IV-172
39. Targeted Genetics Corporation (USA) IV-173
Table 92: Annual Sales Analysis: 2003-2004 (In US$
million) IV-174
40. Telik, Inc. (USA) IV-180
41. Zonagen, Inc. (USA) IV-182
42. Zycos, Inc. (USA) IV-184